Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: SELL (auto-tracking)
0.89% $4.53
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 1 326.30 mill |
EPS: | -0.510 |
P/E: | -8.88 |
Earnings Date: | May 02, 2024 |
SharesOutstanding: | 292.78 mill |
Avg Daily Volume: | 1.458 mill |
RATING 2024-03-28 |
---|
B- |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Neutral | |
P/E: | Strong Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -8.88 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-1.51x |
Company: PE -8.88 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$-4.02 (-188.72%) $-8.55 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 4.27 - 4.79 ( +/- 5.74%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-26 | Hansen Carl L. G. | Sell | 56 125 | Share option (right to buy) |
2024-02-26 | Hansen Carl L. G. | Buy | 56 125 | Common Shares |
2024-01-14 | Lecault Veronique | Buy | 770 416 | Share option (right to buy) |
2024-01-14 | Stimart Tryn | Buy | 616 333 | Share option (right to buy) |
2024-01-14 | Booth Andrew | Buy | 770 416 | Share option (right to buy) |
INSIDER POWER |
---|
79.79 |
Last 95 transactions |
Buy: 16 009 839 | Sell: 26 316 378 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $4.53 (0.89% ) |
Volume | 0.927 mill |
Avg. Vol. | 1.458 mill |
% of Avg. Vol | 63.61 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $5.03 | N/A | Active |
---|
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.